Center for Rare Diseases and Birth Defects, Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Gemelli 8, 00168, Rome, Italy.
Pediatric Neurology Unit, Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Orphanet J Rare Dis. 2021 Jan 22;16(1):43. doi: 10.1186/s13023-021-01674-y.
Costello syndrome (CS) and cardio-facio-cutaneous syndrome (CFCS) belong to the RASopathies, a group of neurodevelopmental disorders with skeletal anomalies. Due to their rarity, the characterization of the musculo-skeletal phenotype in both disorders has been poorly characterized.
Herein we reported data on orthopedic findings and functional status of a large sample of CS and CFCS patients. Thirty-four patients (CS = 17 and CFCS = 17) were recruited. Functional and disability evaluations were performed by assessing the 6-min walking test (6MWT) and Pediatric Outcomes Data Collection Instrument (PODCI). Genotype/phenotype correlation was also provided.
Orthopedic manifestations are highly prevalent in CS and CFCS and overlap in the two disorders. Overall, patients with CS harboring the recurrent HRAS Gly12Ser substitution show a more severe skeletal phenotype compared to patients carrying the Gly12Ala and Gly13Cys variants. Among CFCS patients, those with the MAP2K1/2 variant show different skeletal characteristics compared to BRAF variants, with a higher prevalence of orthopedic abnormalities. Functional assessment showed that patients with CS and CFCS reached lower values compared to the general population, with CFCS patients displaying the lowest scores.
Orthopedic manifestations appear universal features of CS and CFCS and they can evolve across patients' life. Longitudinal assessment of disability status by using 6MWT and PODCI could be useful to evaluate the functional impact of orthopedic manifestations on patients' outcome and help planning a tailored treatment of these comorbidities.
Costello 综合征(CS)和心面 cuts 综合征(CFCS)属于 RASopathy,这是一组具有骨骼异常的神经发育障碍。由于其罕见性,两种疾病的肌肉骨骼表型特征描述都很差。
在此,我们报告了大量 CS 和 CFCS 患者的骨科发现和功能状态数据。共招募了 34 名患者(CS = 17,CFCS = 17)。通过评估 6 分钟步行试验(6MWT)和儿科结局数据采集工具(PODCI)来进行功能和残疾评估。还提供了基因型/表型相关性。
CS 和 CFCS 中骨科表现非常普遍,两种疾病存在重叠。总体而言,携带 HRAS Gly12Ser 重复突变的 CS 患者比携带 Gly12Ala 和 Gly13Cys 变体的患者具有更严重的骨骼表型。在 CFCS 患者中,携带 MAP2K1/2 变异的患者与 BRAF 变异患者的骨骼特征不同,具有更高的骨科异常患病率。功能评估显示,CS 和 CFCS 患者的得分低于一般人群,而 CFCS 患者的得分最低。
骨科表现似乎是 CS 和 CFCS 的普遍特征,并且它们可能在患者的一生中发生演变。使用 6MWT 和 PODCI 对残疾状态进行纵向评估,有助于评估骨科表现对患者预后的功能影响,并有助于制定这些合并症的个体化治疗方案。